Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Circulating Tumor Cells
Interventions: DRUG: trastuzumab
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: Hoffmann-La Roche|Janssen Diagnostics, LLC|SUCCESS|UNICANCER